山东新华制药股份(00719.HK)建议采纳股票期权计划
格隆汇10月28日丨山东新华制药股份(00719.HK)公吿,公司谨此公布,董事会已通过建议的股票期权计划及其建议的授予。股票期权计划须经国资委备案及将由股东于临时股东大会以及类别股东大会批准(包括华鲁控股批准)后生效。股票期权计划可能根据国资委的要求进行修改。
股票期权计划目的是为了进一步建立、健全公司长效激励机制,吸引和留住优秀人才,奖励本公司的董事、高级管理人员、中层管理人员及核心骨干成员的积极性,有效地将股东利益与本公司业务经营的负责人的利益结合起来,协助各订约方共同关注本公司的长远发展和前景。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.